Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Appili Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Appili TherapeuticsDer Umsatz und der Gewinn des Unternehmens werden voraussichtlich um 118.3% bzw. 28.6% pro Jahr zurückgehen, während der Gewinn pro Aktie voraussichtlich zurückgehen wird.

Wichtige Informationen

-28.6%

Wachstumsrate der Gewinne

-5.7%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	71.7%
Wachstumsrate der Einnahmen	-118.3%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	06 Dec 2023

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Market Sentiment Around Loss-Making Appili Therapeutics Inc. (TSE:APLI)

Mar 24

Appili Therapeutics Inc.'s (TSE:APLI) Shift From Loss To Profit

Dec 09

Gewinn- und Umsatzwachstumsprognosen

TSX:APLI - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CAD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
3/31/2026	N/A	-11	N/A	N/A	1
3/31/2025	N/A	-10	N/A	N/A	1
3/31/2024	N/A	-7	N/A	N/A	1
12/31/2023	1	-5	-3	-3	N/A
9/30/2023	1	-8	-4	-4	N/A
6/30/2023	0	-8	-7	-7	N/A
3/31/2023	0	-9	-10	-10	N/A
12/31/2022	N/A	-10	-13	-13	N/A
9/30/2022	1	-11	-18	-18	N/A
6/30/2022	1	-20	-17	-17	N/A
3/31/2022	1	-25	-19	-19	N/A
12/31/2021	1	-27	-20	-20	N/A
9/30/2021	N/A	-28	-17	-17	N/A
6/30/2021	N/A	-19	-17	-17	N/A
3/31/2021	N/A	-14	-11	-11	N/A
12/31/2020	N/A	-11	-8	-8	N/A
9/30/2020	0	-8	-6	-6	N/A
6/30/2020	0	-6	-4	-4	N/A
3/31/2020	0	-5	-4	-4	N/A
12/31/2019	0	-5	-4	-4	N/A
9/30/2019	N/A	-5	-5	-5	N/A
6/30/2019	N/A	-6	-4	-4	N/A
3/31/2019	N/A	-4	-3	-3	N/A
12/31/2018	N/A	-4	-4	-4	N/A
3/31/2018	N/A	-4	-3	-3	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: APLI wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: APLI wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: APLI wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: APLI wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: APLI wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von APLI in 3 Jahren voraussichtlich hoch sein wird

Appili Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

No longer forecast to breakeven

No longer forecast to breakeven

Price target decreased to CA$0.25

Price target decreased to CA$1.27

Price target decreased to CA$2.12

Forecast breakeven pushed back to 2023

Recent updates

Adivir, Inc. entered into a definitive agreement to acquire Appili Therapeutics Inc. (TSX:APLI) for $6.7 million.

Less than half of directors are independent

Appili Therapeutics Inc. Secures Commitment for Second Stage of Funding for ATI-1701 from U.S. Air Force Academy

Appili Therapeutics Announces U.S. FDA Approval of Likmez (ATI-1501) Metronidazole Oral Suspension

Appili Therapeutics Inc., Annual General Meeting, Sep 27, 2023

No longer forecast to breakeven

Appili Therapeutics Inc. and Saptalis Pharmaceuticals LLC Announce That FDA Accepts the ATI-1501 NDA

Appili Therapeutics Inc. Announces Executive Appointments

Appili Therapeutics Inc. Announces Notice of Allowance from the U.S. Patent and Trademark Office for ATI-1501 Liquid Oral Reformulation of Metronidazole

Appili Therapeutics Inc. Promotes Don Cilla to the Position of Chief Executive Officer

Appili Therapeutics Inc., Annual General Meeting, Sep 22, 2022

No longer forecast to breakeven

Appili Therapeutics Inc. announced that it expects to receive $10 million in funding from Defense Threat Reduction Agency

Appili Therapeutics Inc. has completed a Composite Units Offering in the amount of CAD 4.5 million.

Appili Therapeutics Inc. has completed a Composite Units Offering in the amount of CAD 4.5 million.

Price target decreased to CA$0.25

Appili Therapeutics Announces New Late-Stage Clinical Program ATI-1801 to Treat Cutaneous Leishmaniasis

Appili Therapeutics Inc. announced that it expects to receive CAD 4.504032 million in funding from Long Zone Holdings Inc.

Appili Therapeutics Inc. Announces Over $10 Million in New Funding from US Department of Defense for Biodefense Vaccine Candidate ATI-1701

Price target decreased to CA$1.27

Appili Therapeutics Announces Last Patient Enrolled in Phase 3 Trial of Oral Avigan/Reeqonus for the Treatment of Mild-to-Moderate COVID-19

Appili Therapeutics Inc. announced that it has received $1 million in funding from FUJIFILM Toyama Chemical Co., Ltd.

Appili Therapeutics Inc. Announces Completion of Patient Enrollment for Avigan Reeqonus Viral Shedding Sub- Study for Mild-To-Moderate Covid-19 Patients

Price target decreased to CA$2.12

Appili Therapeutics Inc. announced that it has received CAD 3.395 million in funding from The Lind Partners, LLC

Appili Therapeutics Inc. announced that it expects to receive CAD 3.5 million in funding from The Lind Partners, LLC

Forecast breakeven pushed back to 2023

Appili Therapeutics Inc. Expands Preseco Clinical Trial of Avigan®/Reeqonus™ for Mild-To-Moderate Covid-19 Patients into Mexico and Brazil

Independent Data Safety Monitoring Board Recommends Appili Therapeutics Inc. Complete its Phase 3 Avigan®/Reeqonustm Trial for Mild- To-Moderate COVID-19 Patients

Independent Data Safety Monitoring Board Recommends Appili Therapeutics Complete its Phase 3 Avigan/Reeqonus Trial for Mild-to-Moderate COVID-19 Patients

Market Sentiment Around Loss-Making Appili Therapeutics Inc. (TSE:APLI)

New 90-day low: CA$0.96

Earnings beat expectations, revenue disappoints

Appili Therapeutics Inc. Appoints Rochelle Stenzler as Board of Directors

Appili Therapeutics Provides Enrollment Update for Its Phase 3 PRESECO Trial Evaluating the Oral Antiviral Favipiravir as an Early Treatment in COVID-19

New 90-day low: CA$1.02

Appili Therapeutics Inc.'s (TSE:APLI) Shift From Loss To Profit

First Patient Dosed in Appili Therapeutics’ Phase 3 Clinical Trial of Avigan® Tablets (Favipiravir) for the Treatment of COVID-19 in the United States

Appili Therapeutics Inc Announces Initiation of its Phase 3 Post Exposure Prophylaxis for Covid-19 (Pepco) Study to Evaluate Avigan® Tablets (Favipiravir) in the Prevention of Covid-19

Earnings miss expectations

New 90-day high: CA$1.50

Appili Therapeutics Joins Dr. Reddy's, Global Response Aid, and Fujifilm in Advancing Avigan Tablets for the Potential Treatment of Covid-19

Appili Therapeutics Inc. Announces Appointment of Don Cilla as Chief Development Officer, Effective November 1, 2020

Appili Therapeutics Inc. Announces Updates for the Continued Development of its ATI-1701 Biodefense Vaccine Program

New 90-day high: CA$1.19

New 90-day low - CA$0.86

Price target lowered to CA$3.03

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken